Drug Profile
AMG 167
Alternative Names: AMG-167Latest Information Update: 28 Jan 2019
Price :
$50
*
At a glance
- Originator Amgen
- Class Antibodies; Osteoporosis therapies
- Mechanism of Action SOST protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Metabolic bone diseases
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for phase-I development in Metabolic bone diseases(In volunteers) in USA (IV)
- 28 Jan 2019 No recent reports of development identified for phase-I development in Metabolic bone diseases(In volunteers) in USA (SC)
- 03 Jan 2017 Phase I development for AMG 167 is ongoing in USA